Circulating Tumor DNA (ctDNA): A Technology That Can Detect Cancer 3 Years Earlier

🔬 New Hope for Early Diagnosis: ctDNA

Circulating tumor DNA (ctDNA) is genetic material released into blood by cancer cells. Johns Hopkins researchers published findings on 4 July 2025 in Cancer Discovery showing that ctDNA may be detectable years before clinical symptoms.

🕒 Scientific Development: Step by Step

🧪 Phase I: Early Plasma Analysis

Early plasma from 26 cases and 26 controls was assessed with a targeted driver-gene panel. In 7 cases, 1-3 mutations were found. All these individuals received a cancer diagnosis within 0.4 - 3.7 months .

🧪 Phase II: Very Early Plasma Analysis

Of 7 positive cases, 6 also had samples dating from 3.1 – 3.5 years before diagnosis. Mutations were found in 2 samples, but MAF was 8.6 to 79 times lower.

🧬 A Deeper Look with WGS

cfDNA from 45 participants underwent low-depth WGS analysis. INDIA 2207 had aneuploidy and was diagnosed with cancer just 2.8 months later.

🔍 Greater Sensitivity with Personalized Panels

• INDIA 2225 and 2228: Mutations were detected again, with MAF respectively 50x and 79x lower.
• INDIA 2233: Initially negative, but a personalized panel detected a mutation. MAF: 9x lower.
• INDIA 2207: 63% of mutations were successfully detected. MAF: 40x lower.

🧬 Key Findings and Implications for Cancer Screening

The study provides crucial insight into ctDNA-based early-detection potential:

🧪 Rigorous Methodology and Design

This noninterventional study used prospectively collected ARIC plasma samples. Positive results did not change the natural clinical course, allowing investigators to assess the true detection timeline.

🔍 Two-Pronged Analysis: More Mutations, Greater Sensitivity

• Targeted driver-gene panels and personalized whole-genome sequencing (WGS)-based panels were used.
• WGS increased detection from a median of 2 mutations to 39 mutations .

🧬 Aneuploidy Analysis: An Alternative Biomarker

In addition to mutation analysis, aneuploidy testing successfully identified abnormal chromosome numbers. This multimodal approach increased sensitivity.

📈 Sensitivity and Detection Limits

⚠️ Limitations and Future Steps

📌 Pilot Study Size

Very early plasma was analyzed in only 7 participants ; larger cohorts are needed for generalizability.

📌 Improving Sensitivity

• Larger Plasma Volumes: Volumes such as 10 mL may improve detection.
• Multiple Analytes: Combining mutations, aneuploidy, methylation, proteomics, RNA and fragmentomics is proposed.

📌 Real-World Validity

Larger population-based studies and follow-up strategies improving specificity are needed.